Heat Biologics inks license deal with ProBioGen
German contract development and manufacturing company ProBioGen yesterday announced that they have entered into a research license agreement with US biotech Heat Biologics (Nasdaq: HTBX) for both ProBioGen's Transposase System DirectedLuck as well as for its proprietary suspension HEK293 cell line.
Financial terms of the deal were not disclosed, but Heat Biologics’ shares closed down 4.5% at $6.43 following the announcement yesterday.
DirectedLuck has been optimized to recognize specific epigenetic marks. It guides the transgene to regions with highest transcriptional activity. This ensures extraordinarily high protein expression and maximal stability.
The DirectedLuck Transposase is compatible with additional genetic elements in standard expression vector design and can be used with any host cell line. ProBioGen's HEK293 has been optimized for manufacture of proteins and viral vectors and is distinguished by robust growths in chemically defined medium in suspension culture, making it a valuable tool for production in large bioreactors.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze